| Market Cap | 35.60M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -4.74M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 44.00% |
| Sales | 35.89k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 27.00% |
| Dividend | N/A | Price/Book | 10.32 | EPS next 5Y | - | 52W High Chg | -15.00% |
| Recommedations | - | Quick Ratio | 2.00 | Shares Outstanding | 156.82M | 52W Low Chg | 147.00% |
| Insider Own | 2.09% | ROA | -63.46% | Shares Float | 153.55M | Beta | 0.40 |
| Inst Own | - | ROE | -141.63% | Shares Shorted/Prior | -/- | Price | 0.23 |
| Gross Margin | 64.86% | Profit Margin | - | Avg. Volume | 47,635 | Target Price | - |
| Oper. Margin | -13,381.58% | Earnings Date | May 2 | Volume | 23,300 | Change | -0.26% |
Ventripoint Diagnostics Ltd., a medical device company, engages in the development and commercialization of diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers; VMS+ software for use in creating three-dimensional model that generates accurate heart volumetric measurements. It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pulmonary hypertension, cardiotoxicity of chemotherapy treatments for cancer, and Covid-19 related heart issues. The company was incorporated in 2005 and is headquartered in Toronto, Canada.